The Trump administration has initiated a Section 301 investigation into Germany's pharmaceutical pricing practices. U.S. officials allege that Germany consistently underpays for innovative drugs developed in the United States, a practice they argue shifts higher costs onto American patients and hinders U.S. innovation.
The investigation, announced by U.S. Trade Representative Jamieson Greer, targets what the administration describes as Germany's "persistent underpayment for innovative pharmaceutical products." According to the administration's view, countries like Germany have historically mandated steep discounts on medications, making them artificially inexpensive within those markets. This, in turn, forces U.S. pharmaceutical companies to recoup their substantial research and development costs, which average approximately $2.7 billion per new drug, from consumers in markets like the United States, where prices are consequently higher.
Officials contend that this disparity is unjust, particularly as German citizens use the same medications as Americans but do not contribute as much toward their development. The administration points to a previous instance involving the United Kingdom, which reportedly agreed to pay more for U.S. drugs after facing the threat of U.S. tariffs. The current investigation into Germany is expected to continue into the fall, with a public hearing scheduled for September 22. If the administration determines that Germany has engaged in unfair practices, potential retaliatory measures, such as tariffs, could be imposed.
The administration's stated goal is to negotiate fairer pricing agreements that would lower prescription drug costs for Americans and ensure that U.S. pharmaceutical companies can continue to invest in developing new treatments and cures. The focus on international drug pricing is part of a broader effort by the Trump administration to address healthcare costs within the United States.